Blue Light Cystoscopy (BLC) using hexaminolevulinate (Cysview) improves the detection of non-muscle invasive bladder cancer (NMIBC) compared to white light cystoscopy (WLC) alone. However, it is not approved for immediate post-BCG therapy or for repeat use. We report on our experience from the prospective Blue Light Cystoscopy with Cysview Registry and its utility in these scenarios.